Abbisko hoovers up USD 70m in Series C, led by Temasek

Shanghai-based biotech Abbisko Therapeutics Co., Ltd announced completion of a Series C financial round at USD 70 million. The round was led by Temasek, with contributions from Qiming Venture Partners, Jianxin Capital, Government of Singapore Investment Corporation (GIC), Lilly Asia Ventures, CICC Capital, and Loyal Valley Innovation Capital, all existing partners. As GBI reported, Abbisko nailed US 42 million via the Series B one year ago.

Abbisko is an emerging novel drug research and development biotech founded in 2016 in Zhang Jiang High-Tech Park. The firm will use finance round proceeds to advance four drug candidates in clinical development, and push forward multiple pre-clinical candidates.

ABSK021 and ABSK011, both in-house developed small-molecule anti-cancer drugs, have obtained clinical trial approvals in the US, mainland China, and Taiwan. Abbisko has also in-licensed cancer drug candidates under Phase II/III clinical development from AstraZeneca and X4Pharmaceuticals.


Related news
China-based Luye Pharma Group (2186.HK) revealed its 2019 full-year performance numbers, with revenues up 22.9% year-on-year (YOY) to RMB 6.36 billion (USD 899) million.
UK-based AstraZeneca last week obtained marketing authorization from Argentina’s National Administration of Drugs, Food and Medical Technology (ANMAT) for its anti-asthma drug Fasenra (benralizumab), as GBI analysis reveals.
Chinese research into the impact of the new coronavirus linked pneumonia COVID-19 on cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells have provided a boost to French biotech Innate Pharma SA (NASDAQ:IPHA).
  • 1585015284978
  • China
  • R&D
Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) platform released a notification in relation to volume-based procurement (VBP) in the city.
Shanghai-based biotech Zai Lab Ltd (NASDAQ:ZLAB) announced a supplementary New Drug Application (sNDA) filing for its poly (ADP-ribose) polymerase (PARP) inhibitor Zejula (niraparib) is now under review by the National Medical Products Administration (NMPA).
Recent news
GBI recently had the opportunity to talk with Dr. Lu Xianping, the president and co-founder of one of China’s earliest innovation-focused biotechs, Shenzhen Chipscreen Bioscience.
  • 1585728801763
  • China
The outbreak of the novel coronavirus first detected in China in 2019 (2019-nCoV) and its associated disease, COVID-19, has spiralled into a generational healthcare challenge of global scale.
  • 1585728673006
  • China
US-based, China-focused biotech BeyondSpring Inc., (NASDAQ: BYSI) announced the initiation of a rolling New Drug Application (NDA) for plinabulin as a treatment for chemotherapy induced neutropenia (CIN).
  • 1585724852082
  • China
  • Drug
Fujian's provincial Healthcare Security Administration bureau released a notification in relation to pricing of Type A drugs on the National Reimbursement Drug List (NRDL).
China-based biotech Brii Biosciences has moved in to sign up Tsinghua University and the 3rd People’s Hospital of Shenzhen to a licensing agreement, after researchers at the two institutions identified multiple neutralizing monoclonal antibodies (mAbs) with therapeutic potential against SARS CoV-2 and COVID-19.
China-based Hansoh Pharmaceutical Group Co., Ltd (HKEX.3692) released its Q4 2019 financial report.
China-based internet healthcare provider Ping An Healthcare and Technology Co., Ltd (1833.HK), also known as Ping An Good Doctor, announced that its Internet hospital has been linked with the online Basic Medical Insurance (BMI) scheme settlement system in Hubei province.
Analytics Snapshot

Analytics Snapshot